Take a look at the businesses making headlines in premarket buying and selling: Novo Nordisk — The inventory jumped about 5%, rebounding from the practically 18% losses seen within the earlier session. On Friday, the Danish pharmaceutical large’s experimental weight reduction drug, CagriSema, reported late-stage trial outcomes that missed expectations . Honda — U.S.-listed shares surged 15% after the corporate formally started merger talks with fellow Japanese automaker Nissan. The automakers plan to conclude discussions in June 2025. Xerox — The doc providers supplier added practically 7% after asserting its acquisition of printer maker Lexmark. The deal is value $1.5 billion. Occidental Petroleum , Sirius XM , Verisign — The shares continued to rise in Monday’s premarket after Warren Buffett disclosed final week that his Berkshire Hathaway conglomerate added to its stake in every identify. Occidental and Sirius XM every climbed greater than 2%, whereas VeriSign superior 1.8%. Tesla — The electrical car maker bounced 3% earlier than the bell, regaining some floor after final week’s decline. Tesla slid 3.5% final week, which marked its worst weekly efficiency since earlier than the U.S. presidential election. Despegar.com — Shares soared 32% after Prosus entered right into a definitive settlement to purchase the Argentina-based on-line journey platform for $19.50 per share. Prosus can pay $1.7 billion as a part of the deal, which is predicted to shut within the second quarter of 2025. Traws Pharma — Shares of the clinical-stage virology firm skyrocketed greater than 76% after it introduced progress within the improvement of its remedy for H5N1 fowl flu. The corporate stated tivoxavir marboxil confirmed security and tolerability within the section 1 trial, and it’ll start a section 2 research early subsequent yr. The information comes as the specter of fowl flu is predicted to rise. Immunocore — The biotech inventory rose greater than 5% on phrase that the primary affected person has been dosed with its experimental immunotherapy remedy IMC-0115C. — CNBC’s Sean Conlon and Christina Cheddar Berk contributed reporting.
